First-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorReck, M.
dc.contributor.authorCiuleanu, T-E.
dc.contributor.authorCobo, M.
dc.contributor.authorSchenker, M.
dc.contributor.authorZurawski, B.
dc.contributor.authorMenezes, J.
dc.contributor.authorRichardet, E.
dc.contributor.authorBennouna, J.
dc.contributor.authorCheng, Y.
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorLu, S.
dc.contributor.authorJohn, T.
dc.contributor.authorPadilla, B.
dc.contributor.authorSun, X.
dc.contributor.authorMoisei, A.
dc.contributor.authorYan, J.
dc.contributor.authorYuan, Y.
dc.contributor.authorBlum, S. I.
dc.contributor.authorCarbone, D. P.
dc.contributor.authoraffiliation[Reck, M.] German Ctr Lung Res, LungClin, Airway Res Ctr North, Dept Thorac Oncol, Grosshansdorf, Germany
dc.contributor.authoraffiliation[Ciuleanu, T-E.] Inst Oncol Prof Dr Ion Chiricuta, Med Oncol Dept, Cluj Napoca, Romania
dc.contributor.authoraffiliation[Ciuleanu, T-E.] UMF Iuliu Hatieganu, Cluj Napoca, Romania
dc.contributor.authoraffiliation[Cobo, M.] Hosp Carlos Haya Malaga, Dept Med Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Schenker, M.] Sf Nectarie Oncol Ctr, Dept Med Oncol, Craiova, Romania
dc.contributor.authoraffiliation[Zurawski, B.] Ambulatorium Chemioterapii, Chemotherapy Ambulatory, Bydgoszcz, Poland
dc.contributor.authoraffiliation[Menezes, J.] Hosp Nossa Senhora da Conceicao, Dept Clin Oncol, Porto Alegre, RS, Brazil
dc.contributor.authoraffiliation[Richardet, E.] Inst Oncol Cordoba, Dept Oncol, Cordoba, Argentina
dc.contributor.authoraffiliation[Bennouna, J.] Univ Hosp Nantes, Thorac Oncol Unit, Nantes, France
dc.contributor.authoraffiliation[Cheng, Y.] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
dc.contributor.authoraffiliation[Paz-Ares, L.] Univ Complutense, Hosp Univ 12 Octubre, Dept Med Oncol, CNIO H12o Lung Canc Unit, Madrid, Spain
dc.contributor.authoraffiliation[Paz-Ares, L.] CiberOnc, Madrid, Spain
dc.contributor.authoraffiliation[Lu, S.] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Dept Oncol, Shanghai, Peoples R China
dc.contributor.authoraffiliation[John, T.] Austin Hosp, Dept Med Oncol, Heidelberg, Vic, Australia
dc.contributor.authoraffiliation[Padilla, B.] Adelphi Values, Patient Ctr Outcomes, Boston, MA USA
dc.contributor.authoraffiliation[Sun, X.] Adelphi Values, Patient Ctr Outcomes, Boston, MA USA
dc.contributor.authoraffiliation[Moisei, A.] Adelphi Values, Patient Ctr Outcomes, Boston, MA USA
dc.contributor.authoraffiliation[Yan, J.] Bristol Myers Squibb Co, Global Clin Dev, Princeton, NJ USA
dc.contributor.authoraffiliation[Yuan, Y.] Bristol Myers Squibb Co, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA
dc.contributor.authoraffiliation[Blum, S. I.] Bristol Myers Squibb Co, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA
dc.contributor.authoraffiliation[Carbone, D. P.] Ohio State Univ, Ctr Comprehens Canc, Internal Med, Columbus, OH 43210 USA
dc.contributor.funderBristol-Myers Squibb Company
dc.date.accessioned2025-01-07T12:14:41Z
dc.date.available2025-01-07T12:14:41Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.2292
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420423749/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24352
dc.identifier.wosID573469102690
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.numberS1187-S1188
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleFirst-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía